Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

24027 reported adverse events

Drugs of this class: NEVIRAPINE EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE ETRAVIRINE EFAVIRENZ EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE DORAVIRINE DORAVIRINE, ISLATRAVIR DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE

These side effects are most commonly reported by patients taking drugs of the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class:

# Side effect Count
0 FOETAL EXPOSURE DURING PREGNANCY 1802
1 DRUG RESISTANCE 1729
2 VIROLOGIC FAILURE 1709
3 VIRAL MUTATION IDENTIFIED 1313
4 DRUG INTERACTION 1218
5 DEATH 1073
6 PATHOGEN RESISTANCE 1063
7 ANAEMIA 861
8 DRUG INEFFECTIVE 834
9 PYREXIA 806
See all common reactions for Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Drugs of the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA 94 0.7287
1 ULTRASOUND ANTENATAL SCREEN 51 0.5312
2 HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION 147 0.5288
3 HIV-ASSOCIATED NEUROCOGNITIVE DISORDER 48 0.4324
4 VIRAL MUTATION IDENTIFIED 1313 0.3561
5 IMMUNE RECONSTITUTION SYNDROME 453 0.3509
6 HIV VIRAEMIA 72 0.3429
7 VIROLOGIC FAILURE 1709 0.3175
8 MITOCHONDRIAL TOXICITY 206 0.2509
9 LIPODYSTROPHY ACQUIRED 512 0.2409
See all enriched reactions for Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]